@entity2643 and sustained XXXX : statistical evidence of drug effectiveness.

@entity1 @entity1164 @entity2643 @entity296 @entity299 @entity453 @entity943 @entity1002
Previous studies have shown that @entity2643 prevents sustained @entity943 in 77% to 93% of @entity1 . To date, a study using statistical analysis to verify the drug's effectiveness has not been reported. @entity2643 was given to 17 @entity1 with drug refractory sustained @entity943 . All @entity1 had serious underlying @entity299 including @entity453 (15 @entity1 ) or @entity296 (two @entity1 ). Ten @entity1 had angiographic evidence of a @entity1002 . All @entity1 had @entity1002 . The mean left ventricular ejection fraction was 33%. In the 5.5 +/- 8.3 months prior to @entity2643 , these 17 @entity1 had documented sustained @entity943 requiring countershock (41 episodes), overdrive pacing (four episodes), or intravenous drugs (three episodes). @entity2643 was given as a loading dose (1 gm/day for 10 days) and a maintenance dose (200 to 600 mg/day). During a follow-up period of 8.9 +/- 5.7 months, only eight episodes occurred requiring countershock (5) or overdrive pacing (2); one @entity1 died suddenly. A statistical test constructed for this problem showed a significant (p greater than 0.001) reduced risk of experiencing a sustained @entity943 after @entity2643 . This statistical model confirms previous studies showing that @entity2643 prevents sustained @entity943 and prevents @entity1164 .
